Our Company

At T2 Biosystems, our mission is to save lives and improve healthcare by empowering clinicians to effectively treat patients faster than ever before.

Our proven T2 Magnetic Resonance (T2MR®) technology is transforming diagnostics by providing accurate and actionable information to doctors when it matters most. Today, T2 tests are improving the quality of care and savings hospitals millions of dollars each year. The FDA-cleared T2Candida® Panel is available in over 130 hospitals and our European presence now includes 10 countries. 

At T2 Biosystems, we focus on critical unmet needs in healthcare diagnostics, choosing targets based on the prevalence and frequency of ineffective treatment due to shortcomings in current diagnostics. This approach made sepsis, one of the deadliest and the most expensive conditions in hospitals today, a natural first choice. 

The T2Sepsis Solution™ starts with theT2Candida Panel that runs on the T2Dx® Instrument and can detect the five most clinically relevant species of Candida in 3 to 5 hours—directly from the patient’s blood and without the need for blood culture. The sepsis-causing pathogen Candida has a staggering average mortality rate of approximately 40%.1 Today, hospitals like Henry Ford Health System in Michigan2 and Lee Health System in Florida,3 both of which use T2 products, are reporting that patients are getting on the right therapy—and off unnecessary therapy—much faster. The results are changing healthcare: length of stay for patients, along with healthcare costs, are going down. In addition to expediting patient care: 

  • The T2Candida Panel is extremely accurate with a proven sensitivity of over 90%, while blood culture is only 50% in comparison.4,5 
  • The specificity of T2 panels is over 99%, so doctors can have confidence in a negative result.4 
  • T2MR technology is now detecting complex conditions that blood culture often misses, such as fungal lung infections. 

In cases where doctors had no actionable information on which to base their decisions, T2MR technology is now enabling the lab and physicians to partner to provide more targeted treatment. 

The rapid and accurate T2 results are critical weapons in the hospital’s fight against antimicrobial resistance: 

  • T2 results reduce the overuse of antimicrobial therapies by getting doctors and hospitals specific pathogen identification information faster than ever before. Positive results enable targeted treatment, and negative results may allow physicians to limit or eliminate the use of unnecessary drugs. 

This responsible stewardship combats drug resistance and superbugs, helping ensure these crucial treatments are available for generations to come.

What’s next? The T2Bacteria™ Panel

We are building on our T2MR technology to provide the T2Sepsis Solution to hospitals. Our next panel, T2Bacteria, is undergoing clinical trials and will be submitted to the FDA mid-2017. The T2Bacteria RUO Panel is currently available for Research Use Only (RUO) in the US. In the EU, performance evaluation studies are in progress and the T2Bacteria Panel will be available as a CE marked product in the coming months.

Thanks to the aggressive efforts of clinicians and hospitals, about 60% of symptomatic patients now receive the appropriate antimicrobial therapy within a 24-hour window. But the limitations of current diagnostic technology leaves about 40% of patients waiting too long for the right diagnosis and treatment. Help is on the way: 

  • With T2 tests for Candida and key bacterial species, hospitals will be able to treat 95% of patients appropriately within the first 12 hours of the critical care window. 
  • Other ongoing development efforts in our pipeline include bacterial resistance panels and a hemostasis diagnostic, as well as Lyme disease panel through a partnership with Canon U.S.A.

Why does it matter that T2 tests can be done from whole blood; that is, without blood culture?

T2’s no-blood-culture-required approach to sepsis pathogen detection means hospitals get results in hours, not days. When research tells us the mortality rate for sepsis rises by 8% every hour,6 waiting days for results is just not good enough.

And because T2 products do not require the growth of cells like blood culture tests, over 90% of infections are detected—instead of the 50% to 65% detection rate for blood culture.7 Hospitals know that delivering the appropriate care for sepsis in less than 24 hours, and ideally 12 hours, is critical for their patients. T2 has the only FDA-cleared and CE marked products that can do that.  

How does the technology behind the T2 test work?

T2 tests are powered by our proprietary T2MR technology platform. T2MR combines proven magnetic resonance with innovative nanotechnology to accurately identify pathogens in whole blood faster and easier than blood-culture-based diagnostics. 

  • T2MR works by measuring how water molecules react in the presence of magnetic fields, utilizing the same magnetic-resonance-based approach found in MRI, but on a miniaturized scale. 
  • Over 200 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications. 
  • With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of in vitro diagnostics.

T2 Biosystems’ use of T2MR technology to help get patients on the right treatment faster has led to multiple recognitions including:

  • Receiving the prestigious Prix Galien USA Best Medical Technology award in 2015. 
  • Being named among the 50 Smartest Companies of 2016 by MIT Technology Review.
  • Recognition of CEO John McDonough as #8 Most Creative Person by Fast Company in 2016. 

In addition, various industry leaders continue to validate the game-changing power of T2MR technology by entering into strategic alliances with T2 Biosystems. In 2016, T2 Biosystems announced partnerships with Canon U.S.A., Allergan and Bayer. 

About our name

T2 refers to the measurement of the reaction of water molecules in the presence of magnetic fields. This is what our T2MR technology measures and is the source of the T2 Biosystems name.

……………………………………….
1. Parkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007). Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. Journal of Antimicrobial Chemotherapy, 60(3), 613-618.
2. Wilson, N.M., Kenney, R.M.,  Tibbetts, R.J., et. al.  T2 Magnetic Resonance Improves the Timely Management of Candidemia. Poster Presentation IDWeek 2016.
3. Estrada, S. J. Real World Value of T2Candida Lee Memorial Hospital. Slide Presentation ASM 2016.
4. Mylonakis, E., Clancy, C. J., Ostrosky-Zeichner, L., Garey, K. W., Alangaden, G. J., Vazquez, J. A., … & Zervou, F. N. (2015). T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clinical Infectious Diseases, ciu959.
5. Pappas, P et. al. (2015). Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical infectious diseases, civ933.
6. Kumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., … & Gurka, D. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.
7. Lee, A., Mirrett, S., Reller, L. B., & Weinstein, M. P. (2007). Detection of bloodstream infections in adults: how many blood cultures are needed?. Journal of clinical microbiology, 45(11), 3546-3548.